December 23, 2016 / 12:53 PM / 8 months ago

BRIEF-Helix Biopharma successfully out-licenses late stage Biphasix technology

Dec 23 (Reuters) - Helix Biopharma Corp :

* Under terms of agreement, Xisle has paid an up-front fee and agreed to subsequent milestone payments

* Helix Biopharma Corp - Xisle will be responsible for continued clinical development and subsequent commercialization of product

* Helix Biopharma Corp successfully out-licenses late stage Biphasix technology

* Helix Biopharma Corp - signed exclusive out-license agreement with Xisle Pharma ventures trust for company's late-stage, Biphasix technology platform Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below